Half-year report · HY
6942.TEDINET S100X1E1
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.0bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥8.4bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.2bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | −¥2m | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥300m | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥842,000 | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥322m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥276m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥367,000 | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥95m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥86m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥367,000 | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥86m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥7.0bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥7.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥8.1bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥4.0bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥4.4bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.0bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.0bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.0bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.8bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥3.0bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.0bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥2.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥2.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥2.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥3.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥15m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥261m | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥125m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥75m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥378m | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥147m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥534m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥848m | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥361m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥0.08 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥20.79 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥18.88 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥20.71 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥18.74 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 43.3% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 40.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.2% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥190,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥190,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥13m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥18m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥18m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥253m |
| Dispensing Pharmacy And Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Dispensing Pharmacy And Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Dispensing Pharmacy And Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Dispensing Pharmacy And Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥228m |
| Internet Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥522m |
| Internet Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥518m |
| Internet Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Internet Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥25m |
| Telecommunications Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥109m |
| Telecommunications Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥98m |
| Telecommunications Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥10m |
| Telecommunications Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥10m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥18m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥264m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥18m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥7m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥7m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥28m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥13m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥13m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14m |
| Dispensing Pharmacy And Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| Dispensing Pharmacy And Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| Dispensing Pharmacy And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5m |
| Dispensing Pharmacy And Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥297m |
| Internet Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥679m |
| Internet Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥675m |
| Internet Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Internet Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥48m |
| Telecommunications Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥76m |
| Telecommunications Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥71m |
| Telecommunications Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5m |
| Telecommunications Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥13m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥342m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥13m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥314m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 600
| Item | Context | Value | Unit |
|---|---|---|---|
| Segment profit loss IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -28437000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 313724000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReconcilingItemsMember | -13539000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration | 300185000 | JPY |
| Finance income IFRS | Prior1InterimDuration | 2494000 | JPY |
| Finance costs IFRS | Prior1InterimDuration | 27100000 | JPY |
| Profit loss before tax IFRS | Prior1InterimDuration | 275579000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01978-000InternetRelatedBusinessReportableSegmentMember | 518301000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01978-000TelecommunicationsBusinessReportableSegmentMember | 98343000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01978-000DispensingPharmacyAndRelatedBusinessReportableSegmentMember | 3389303000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReportableSegmentsMember | 4005948000 | JPY |
| Revenue from external customers IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 190000 | JPY |
| Revenue from external customers IFRS | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4006138000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | InterimDuration | 4006138000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000InternetRelatedBusinessReportableSegmentMember | 3320000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000TelecommunicationsBusinessReportableSegmentMember | 10181000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000DispensingPharmacyAndRelatedBusinessReportableSegmentMember | 4200000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReportableSegmentsMember | 17702000 | JPY |
| Intersegment revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 17702000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReconcilingItemsMember | -17702000 | JPY |
| Intersegment revenue IFRS | InterimDuration | － | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000InternetRelatedBusinessReportableSegmentMember | 521622000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000TelecommunicationsBusinessReportableSegmentMember | 108524000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E01978-000DispensingPharmacyAndRelatedBusinessReportableSegmentMember | 3393503000 | JPY |
| Revenue IFRS | InterimDuration_ReportableSegmentsMember | 4023650000 | JPY |
| Revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 190000 | JPY |
| Revenue IFRS | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4023840000 | JPY |
| Revenue IFRS | InterimDuration_ReconcilingItemsMember | -17702000 | JPY |
| Revenue IFRS | InterimDuration | 4006138000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E01978-000InternetRelatedBusinessReportableSegmentMember | 25240000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E01978-000TelecommunicationsBusinessReportableSegmentMember | 10449000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E01978-000DispensingPharmacyAndRelatedBusinessReportableSegmentMember | 227919000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReportableSegmentsMember | 263610000 | JPY |
| Segment profit loss IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -13253000 | JPY |
| Segment profit loss IFRS | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 250356000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReconcilingItemsMember | -252684000 | JPY |
| Segment profit loss IFRS | InterimDuration | -2327000 | JPY |
| Finance income IFRS | InterimDuration | 15173000 | JPY |
| Finance costs IFRS | InterimDuration | 12003000 | JPY |
| Profit loss before tax IFRS | InterimDuration | 842000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-14 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第51期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ソフィアホールディングス | |
| Company name in english cover page | FilingDateInstant | SOPHIA HOLDINGS CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 飯塚 秀毅 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |